Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry

Author(s): MahajanST, Patel PB, Marrie RA

Abstract

Purpose:We describe the prevalence of overactive bladder symptoms in patients with multiple sclerosis as well as the rates of evaluation and treatment of urinary complaints.

Materials and methods:Data from the fall 2005 North American Research Committee On Multiple Sclerosis survey were examined, including the Urogenital Distress Inventory plus a nocturia question, the SF-12, and inquiries regarding urological care and treatments. Data were analyzed using descriptive statistics, chi-square and Student's t tests, ANOVA and multivariable logistic regression.

Results:Of 16,858 surveys distributed 9,702 (58%) were completed. Participants with a surgically altered bladder were excluded from analysis (21). At least 1 moderate to severe urinary symptom (score of 2 or greater) was reported by 6,263 (65%) respondents. Increasing overactive bladder symptoms were correlated with longer disease duration (r = 0.135) and increasing physical disability (r = 0.291) (both p <0.001). Decreased quality of life was associated with increasing disability (p <0.001) and overactive bladder symptom score (p <0.001). Of patients with moderate to severe overactive bladder symptoms only 2,710 (43.3%) were evaluated by urology and 2,361 (51%) were treated with an anticholinergic medication. Treated patients more frequently reported leakage (p <0.001) and newer treatments were significantly underused (less than 10% total use). Catheter use was reported by 2,309 (36.8%) respondents, and was associated with greater disability, higher overactive bladder symptom score and reduced quality of life (all p <0.001).

Conclusions:This large scale study identified high rates of overactive bladder symptoms in patients with MS, and correlations with increasing disease duration and physical disability. Despite an increasing awareness of overactive bladder symptoms and the need for evaluation and treatment, many patients remain underserved.

Similar Articles

A UK consensus on the management of the bladder in multiple sclerosis

Author(s): Fowler CJ, Panicker JN, Drake M, Harris, Harrison SCW, et al.

Disparities in the management of multiple sclerosis-related bladder symptoms

Author(s): MarrieRA, Cutter G, Tyry T, Vollmer T, Campagnolo D

The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines

Author(s): de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF

Urinary complications and risk factors in symptomatic multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, Clanet M, Gasq D, De Boissezon X, et al.

The neural control of micturition

Author(s): Fowler CJ, Griffiths D, de Groat WC

Botulinum toxin treatment for bladder dysfunction

Author(s): Santos-Silva A, da Silva CM, Cruz F

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction

Author(s): Fletcher SG, Dillon BE, Gilchrist AS, Haverkorn RM, Yan J, et al.

First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm

Author(s): Amarenco G, Chartier-Kastler E, Denys P, Jean JL, de Seze M et al.

Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis

Author(s): Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE

Role of cannabinoids in multiple sclerosis

Author(s): Zajicek JP, Apostu VI

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

Author(s): Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Author(s): Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, et al.

The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review

Author(s): Tubaro A, Puccini F, De Nunzio C, Digesu GA, Elneil S, et al.

Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder

Author(s): Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, et al.

Botulinum toxin therapy for neurogenic detrusor overactivity

Author(s): Smaldone MC1, Ristau BT, Leng WW

Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis

Author(s): Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, et al.

Clinical outcomes of sacral neuromodulation in patients with neurologic conditions

Author(s): Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA

Impact of intermittent catheterization on the quality of life of multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, De Boissezon X, Guillotreau J, Braley-Berthoumieux E, et al.